NASDAQ:PACB - Pacific Biosciences of California Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.70 -0.02 (-0.54 %)
(As of 07/16/2018 03:00 AM ET)
Previous Close$3.70
Today's Range$3.63 - $3.76
52-Week Range$2.02 - $5.70
Volume545,947 shs
Average Volume982,793 shs
Market Capitalization$487.94 million
P/E RatioN/A
Dividend YieldN/A
Beta1.51
Pacific Biosciences of California logoPacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.

Receive PACB News and Ratings via Email

Sign-up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNASDAQ:PACB
CUSIP69404D10
Phone650-521-8000

Debt

Debt-to-Equity Ratio0.14
Current Ratio4.64
Quick Ratio3.60

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$93.47 million
Price / Sales5.22
Cash FlowN/A
Price / CashN/A
Book Value$0.74 per share
Price / Book5.00

Profitability

EPS (Most Recent Fiscal Year)($0.87)
Net Income$-92,180,000.00
Net Margins-105.22%
Return on Equity-91.11%
Return on Assets-58.10%

Miscellaneous

Employees456
Outstanding Shares131,880,000
Market Cap$487.94

The Truth About Cryptocurrencies

Pacific Biosciences of California (NASDAQ:PACB) Frequently Asked Questions

What is Pacific Biosciences of California's stock symbol?

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

How were Pacific Biosciences of California's earnings last quarter?

Pacific Biosciences of California (NASDAQ:PACB) announced its quarterly earnings results on Wednesday, May, 2nd. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.01. The biotechnology company had revenue of $19.40 million for the quarter, compared to analyst estimates of $23.97 million. Pacific Biosciences of California had a negative net margin of 105.22% and a negative return on equity of 91.11%. The firm's quarterly revenue was down 22.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.26) earnings per share. View Pacific Biosciences of California's Earnings History.

When is Pacific Biosciences of California's next earnings date?

Pacific Biosciences of California is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Pacific Biosciences of California.

What price target have analysts set for PACB?

2 analysts have issued twelve-month price targets for Pacific Biosciences of California's stock. Their predictions range from $4.00 to $6.80. On average, they anticipate Pacific Biosciences of California's share price to reach $5.40 in the next year. This suggests a possible upside of 45.9% from the stock's current price. View Analyst Ratings for Pacific Biosciences of California.

What is the consensus analysts' recommendation for Pacific Biosciences of California?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."

Who are some of Pacific Biosciences of California's key competitors?

Who are Pacific Biosciences of California's key executives?

Pacific Biosciences of California's management team includes the folowing people:
  • Dr. Michael W. Hunkapiller, Exec. Chairman, CEO & Pres (Age 69)
  • Ms. Susan K. Barnes, Sr. VP & CFO (Age 64)
  • Mr. James Michael Phillips, Sr. VP of R&D (Age 67)
  • Mr. Kevin P. Corcoran, Sr. VP of Market Devel. (Age 59)
  • Ms. Kathy P. Ordoñez, Chief Commercial Officer, Exec. VP & Director (Age 67)

Has Pacific Biosciences of California been receiving favorable news coverage?

News articles about PACB stock have been trending positive recently, according to Accern Sentiment. Accern scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pacific Biosciences of California earned a coverage optimism score of 0.36 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 45.05 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

How do I buy shares of Pacific Biosciences of California?

Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pacific Biosciences of California's stock price today?

One share of PACB stock can currently be purchased for approximately $3.70.

How big of a company is Pacific Biosciences of California?

Pacific Biosciences of California has a market capitalization of $487.94 million and generates $93.47 million in revenue each year. The biotechnology company earns $-92,180,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis. Pacific Biosciences of California employs 456 workers across the globe.

How can I contact Pacific Biosciences of California?

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected]


MarketBeat Community Rating for Pacific Biosciences of California (NASDAQ PACB)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  200 (Vote Outperform)
Underperform Votes:  217 (Vote Underperform)
Total Votes:  417
MarketBeat's community ratings are surveys of what our community members think about Pacific Biosciences of California and other stocks. Vote "Outperform" if you believe PACB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PACB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.